R&D channel feed

Take­da tak­ing mag­ni­fy­ing glass to non-vi­ral gene ther­a­py pro­grams as Carmine pact ends

3 years ago
Cell/Gene Tx

Mer­ck KGaA's BTK in­hibitor hit by par­tial clin­i­cal hold over safe­ty con­cern, but PhI­II read­out un­af­fect­ed

3 years ago
FDA+

Sci­ence-whiz twins backed by a16z bring Func­tion On­col­o­gy out of stealth

3 years ago
Financing

How ARPA-H's new hub-and-spoke mod­el will cre­ate a na­tion­wide re­search net­work

3 years ago
Pharma

Four years lat­er, FDA fi­nal­izes guid­ance on risk-based mon­i­tor­ing of clin­i­cal tri­als

3 years ago
FDA+

Preprint man­date? BioRx­iv and medRx­iv founders call on White House to en­sure ear­ly ac­cess to gov­ern­ment-fund­ed re­search

3 years ago

Up­dat­ed: Mod­er­na: Not enough flu cas­es in PhI­II tri­al yet to tell ef­fi­ca­cy

3 years ago

Take­da joins forces with small pri­vate biotech for pre­clin­i­cal Alzheimer's re­search

3 years ago
Deals

Chi­nook paus­es PhI kid­ney dis­ease tri­al af­ter se­ri­ous ad­verse event

3 years ago

ARCH-backed HI-Bio touts ear­ly da­ta from two tri­als for rare kid­ney dis­ease

3 years ago

Agency ex­pands video gam­ing prac­tice with new pod­cast on 'gamechang­er­s' for phar­ma and health­care

3 years ago

Medicare spend­ing on CLL drugs sky­rock­ets from $254M to $3.7B in 7 years, JA­MA study finds

3 years ago

Mer­ck and Ei­sai's Keytru­da/Lenvi­ma com­bo fails PhI­II tri­als for melanoma, col­orec­tal can­cer

3 years ago

Im­mu­nic touts pos­i­tive da­ta in main­te­nance phase of failed PhII tri­al, pulls back on an­oth­er as­set

3 years ago

Pri­vate start­up claims a PhI­Ia win in sub­set of ALS pa­tients, but ques­tions re­main

3 years ago

Take­da end­ing dis­cov­ery, pre­clin­i­cal work in AAV gene ther­a­py, rare hema­tol­ogy

3 years ago
People
Pharma

AI tools don't equal guar­an­teed drug suc­cess as Benev­o­len­tAI flops der­mati­tis test

3 years ago
AI

Pfiz­er RSV da­ta set up $10B show­down with GSK and Mod­er­na for the next big vac­cine mar­ket

3 years ago
Pharma

Am­gen's deno­sum­ab shows promise in small, NIH-fund­ed rare bone dis­ease study

3 years ago

In­cyte links arms with tiny Bio­th­eryx for pro­tein de­grad­er deal, tar­get­ing can­cer

3 years ago
Deals

Gink­go snaps up gene ther­a­py vec­tor as­sets from Stride­Bio

3 years ago
Deals

As­traZeneca's Lyn­parza-Imfinzi com­bo clears PhI­II tri­al in ovar­i­an can­cer

3 years ago

Es­tée Laud­er's fam­i­ly in­jects $200M in­to Alzheimer’s Drug Dis­cov­ery Foun­da­tion

3 years ago

Ake­bia touts new da­ta on ane­mia drug a year af­ter re­jec­tion

3 years ago
Pharma
First page Previous page 89909192939495 Next page Last page
A service from the Financial Times